Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Description

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Conditions

Preeclampsia

Talk to us

Study Overview

On this page

Study Details

Study overview

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Condition
Preeclampsia
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic Minnesota, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals with \< 34 0/7 weeks of gestation.
  • * Individuals with severe preeclampsia or HELLP features.
  • * Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
  • * Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Maria Lourdes Gonzalez Suarez, MD, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2028-12-31